RT Journal Article
SR Electronic
T1 Biobanking and Cryopreservation of Human Lung Explants for Omic Analysis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1801635
DO 10.1183/13993003.01635-2018
A1 Sarah G. Chu
A1 Sergio Poli De Frias
A1 Yuichi Sakairi
A1 Rachel S. Kelly
A1 Robert Chase
A1 Kazuhisa Konishi
A1 Ashley Blau
A1 Ellen Tsai
A1 Konstantin Tsoyi
A1 Robert F. Padera
A1 Lynette M. Sholl
A1 Hilary J. Goldberg
A1 Hari R. Mallidi
A1 Phillip C. Camp
A1 Souheil Y. El-Chemaly
A1 Mark A. Perrella
A1 Augustine M. K. Choi
A1 George R. Washko
A1 Benjamin A. Raby
A1 Ivan O. Rosas
YR 2019
UL http://erj.ersjournals.com/content/early/2019/10/16/13993003.01635-2018.abstract
AB Recent advances in high throughput omic technologies have greatly enhanced our knowledge of the molecular basis of complex lung diseases. In particular, with the advent of next generation sequencing, transcriptomic studies with RNA sequencing (RNA-seq) have yielded important insights into chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) [1, 2]. However, most studies to date have been performed on whole lung tissue, such that many unique cell type-specific gene expression signatures—particularly those of alveolar epithelial cells (AECs), which play a key role in COPD and IPF—may have been diluted, if not missed altogether. Single-cell RNA-seq is rapidly gaining momentum as a strategy to profile individual cells [3, 4], but sequencing depth is typically much lower and cost much higher than that of bulk RNA-seq.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Chu has nothing to disclose.Conflict of interest: Dr. Poli has nothing to disclose.Conflict of interest: Dr. Sakairi reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Kelly reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Chase reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Konishi reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Ms. Blau reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Tsai reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Tsoyi has nothing to disclose.Conflict of interest: Dr. Padera reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Sholl reports grants from National Institutes of Health, during the conduct of the study; personal fees from Foghorn Therapeutics, outside the submitted work.Conflict of interest: Dr. Goldberg reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Mallidi reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Camp reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. El-Chemaly has nothing to disclose.Conflict of interest: Dr. Perrella reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Choi reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Washko reports grants from NIH, grants and other from Boehringer Ingelheim, other from Genentech, other from Quantitative Imaging Solutions, other from PulmonX, other from Regeneron, other from ModoSpira, grants from BTG Interventional Medicine, grants and other from Janssen Pharmaceuticals, other from Toshiba, other from GlaxoSmithKline, outside the submitted work; and Dr. Washko's spouse works for Biogen which is focused on developing therapies for fibrotic lung disease.Conflict of interest: Dr. Raby reports grants from National Institutes of Health, during the conduct of the study.Conflict of interest: Dr. Rosas reports grants from National Institutes of Health, during the conduct of the study.